This information is intended for patients prescribed apixaban in UK only.
Home / Following Surgery

Following Surgery

Information for adult patients who have been prescribed apixaban for the prevention of venous thromboembolic events (VTE) following elective hip or knee replacement surgery

Patients prescribed apixaban

This section is intended for patients prescribed apixaban in the UK to provide information on this medicine, and its uses. It is not intended to replace in any way the opinion of a healthcare professional. For specific information about the pathology and/or detection, diagnosis, prognosis, administration and, where applicable, appropriate treatment for each specific case, please promptly consult a healthcare professional. The use of this website is subject to the legal notice, the privacy and cookie policy, the pharmacovigilance notice (if appropriate) and the applicable laws and regulations.

Report Side Effects

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

Side effects for this medicine should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com.

You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol-Myers Squibb Company.

Bristol-Myers Squibb Pfizer Logo

© 2018 Bristol-Myers Squibb Pharmaceuticals Limited

All corporate names and logos of BMS and/or of its products are trademarks of Bristol-Myers Squibb Company and are protected by national and international intellectual and industrial property laws. All rights reserved over the content of this website.

Your use of this website is subject to the Legal Notice, the Privacy and Cookie Policy, the Pharmacovigilance Notice and the applicable laws and regulations.

432UK1700565-01
Date of preparation: June 2017